Company profile
Emergent BioSolutions Inc.
NYSE: EBS · Healthcare · Biotechnology
#181 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
69BFH 76DQ 79GM 27SS 77
v0.1 · 65/100 weight · provisional
↑ operating margin, return on assets · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$676.8M
Rev growth YoY (TTM)
-29.9%
Net income (FY)
$52.6M
Employees
900
as of 2026-08-12
Market cap
$229.6M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$742.9M$742.9M2025
Net income$52.6M$52.6M2025
Operating income$100.1M$100.1M2025
Total assets$1.3B$1.3B2025
Liabilities$796.0M$796.0M2025
Equity$522.6M$522.6M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY22
FY22
FY22
FY22
FY25
FY25
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product95%
Contracts and Grants5%
By geography
UNITED STATES71%
Other Geographical Area18%
CANADA10%
The read
What is Emergent BioSolutions Inc.’s revenue?
Emergent BioSolutions Inc. booked $742.9M in FY2025 revenue, contracting 29% year over year — slower than 75% of Healthcare companies we track, at a 7.1% net margin.
Peers · Healthcare
Alphatec Holdings, Inc.77B+Corcept Therapeutics Incorporated84B+iRhythm Technologies, Inc.75B+Repligen Corporation82B+NeoGenomics, Inc.72BPacira BioSciences, Inc.78B+Neighbors
Montgomery →Key facts
CEOJoseph C. Papa Jr.
SectorHealthcare
IndustryBiotechnology
HeadquartersGaithersburg, MD
ExchangeNYSE: EBS
Employees900
IPO date2006-11-15
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.